US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

4.00

+0.15003.90%

Post-market: 4.000.00000.00%16:10 EDT

Volume:29.90K

Turnover:116.19K

Market Cap:47.04M

PE:-3.74

High:4.00

Open:3.81

Low:3.66

Close:3.85

52wk High:9.99

52wk Low:1.98

Shares:11.76M

Float Shares:6.21M

Volume Ratio:1.49

T/O Rate:0.48%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0691

EPS(LYR):-0.7311

ROE:-316.04%

ROA:-96.73%

PB:4.28

PE(LYR):-5.47

Loading ...

Overview Company News Filings

Nasus Pharma CEO Dan Benjamin Teleman buys 2,900 shares for $10,904

Nasus Pharma’s CEO Makes Bold Move With Fresh Insider Buy

Nasus Pharma CEO Dan Benjamin Teleman buys USD 0.03 million shares

Nasus Pharma director David Silberman files initial beneficial ownership statement

Nasus Pharma files Form 3 as director Ronnie Hershman reports beneficial ownership

Nasus Pharma director Sharon Shacham files initial beneficial ownership statement

Nasus Pharma files Form 3 for founder, Chief Development Officer Dalia Megiddo

Nasus Pharma files Form 3 as director Israel Isaac reports beneficial ownership

Nasus Pharma Is Maintained at Market Outperform by Citizens

Nasus Pharma price target lowered to $18 from $19 at Citizens

Nasus Pharma advances NS002 to pivotal study following Phase 2 results

Nasus Pharma FY2025 net loss widens 282% to $5.9 million; revenue records no revenue

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

What's Going On With Nasus Pharma Stock On Wednesday

Benzinga_recent_news

NYSE American New 52-Week Highs And Lows

Nasus Pharma Stock Hits 52-Week Low - Here's Why

Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform

BRIEF-Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold

Nasus Pharma announces topline data from Phase 2 clinical study of NS002

Nasus Pharma Phase 2 trial shows NS002 reaches 100 pg/mL epinephrine threshold in 1.69 minutes vs 3.42 minutes for EpiPen

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NSRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":4,"timestamp":1787342400000,"preClose":3.85,"halted":0,"volume":29896,"hourTrading":{"tag":"盘后","latestPrice":4,"preClose":4,"latestTime":"16:10 EDT","volume":8,"amount":31.84,"timestamp":1787343004773,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03896103896103894,"floatShares":6214000,"shares":11758900,"eps":-1.06915,"marketStatus":"Market Closed","change":0.15,"latestTime":"08-21 16:00:00 EDT","open":3.805,"high":4,"low":3.655,"amount":116190,"amplitude":0.08961,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.06915,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":3.85,"postHourTrading":{"tag":"盘后","latestPrice":4,"preClose":4,"latestTime":"16:10 EDT","volume":8,"amount":31.84,"timestamp":1787343004773,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4934857467309914},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":6214000,"roa":"-96.73%","roe":"-316.04%","lyrEps":-0.731074,"volumeRatio":1.4934857467309914,"shares":11758900,"dividePrice":0,"high":4,"amplitude":0.08961,"preClose":3.85,"low":3.655,"week52Low":1.98,"pbRate":"4.28","week52High":9.9899,"institutionHeld":0,"latestPrice":4,"eps":-1.06915,"divideRate":0,"volume":29896,"delay":0,"ttmEps":-1.06915,"open":3.805,"prevYearClose":9.15,"prevWeekClose":3.62,"prevMonthClose":3.03,"prevQuarterClose":3.5,"fiveDayClose":3.62,"twentyDayClose":3.12,"sixtyDayClose":3.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-08-21","current":-3.74129,"percent":0.988235,"low":-51.389177,"twenty":-44.884218,"median":-29.56931,"eighty":-6.079381,"high":-4.019591,"avg":-25.735836,"sd":17.475109,"marketCap":45086610},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295},{"date":"2026-02-27","current":-31.33863,"twenty":-47.308794,"median":-42.873594,"eighty":-33.62436,"marketCap":59950800},{"date":"2026-03-06","current":-30.662699,"twenty":-47.308794,"median":-41.857638,"eighty":-33.151251,"marketCap":58657744},{"date":"2026-03-13","current":-28.389112,"twenty":-47.308794,"median":-41.483899,"eighty":-32.108896,"marketCap":54308372},{"date":"2026-03-20","current":-15.239177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"marketCap":29152546},{"date":"2026-03-27","current":-4.817647,"twenty":-47.249657,"median":-41.365627,"eighty":-30.724148,"marketCap":28212141},{"date":"2026-04-02","current":-5.099481,"twenty":-47.249657,"median":-40.41945,"eighty":-29.587069,"marketCap":29862560},{"date":"2026-04-10","current":-4.639528,"twenty":-47.202349,"median":-40.212475,"eighty":-29.052754,"marketCap":27169074},{"date":"2026-04-17","current":-4.499542,"twenty":-47.048596,"median":-40.212475,"eighty":-28.102929,"marketCap":26349318},{"date":"2026-04-24","current":-6.799308,"twenty":-46.871188,"median":-39.325435,"eighty":-27.041563,"marketCap":39816747},{"date":"2026-05-01","current":-5.39945,"twenty":-46.741088,"median":-38.438986,"eighty":-25.76289,"marketCap":31619181},{"date":"2026-05-08","current":-6.77931,"twenty":-46.717433,"median":-38.438395,"eighty":-18.667992,"marketCap":39699639},{"date":"2026-05-15","current":-5.939395,"twenty":-46.670125,"median":-36.896469,"eighty":-15.349784,"marketCap":34781099},{"date":"2026-05-22","current":-5.739416,"twenty":-46.374445,"median":-36.254495,"eighty":-7.119275,"marketCap":33610018},{"date":"2026-05-29","current":-6.399349,"twenty":-46.126074,"median":-35.850198,"eighty":-6.399349,"marketCap":37474585},{"date":"2026-06-05","current":-6.47934,"twenty":-46.007802,"median":-35.518691,"eighty":-6.399349,"marketCap":37943017},{"date":"2026-06-12","current":-6.339355,"twenty":-45.901357,"median":-34.571052,"eighty":-6.29136,"marketCap":37123261},{"date":"2026-06-18","current":-6.159373,"twenty":-45.830394,"median":-34.411045,"eighty":-6.175371,"marketCap":36069288},{"date":"2026-06-26","current":-6.599328,"twenty":-45.830394,"median":-33.62436,"eighty":-6.175371,"marketCap":38645666},{"date":"2026-07-02","current":-7.029284,"twenty":-45.771258,"median":-33.505965,"eighty":-6.207368,"marketCap":41163490},{"date":"2026-07-10","current":-6.019387,"twenty":-45.49935,"median":-32.81339,"eighty":-6.167372,"marketCap":35249532},{"date":"2026-07-17","current":-6.139375,"twenty":-45.334124,"median":-32.21535,"eighty":-6.139375,"marketCap":35952180},{"date":"2026-07-24","current":-6.18537,"twenty":-45.191725,"median":-31.392839,"eighty":-6.099379,"marketCap":36221529},{"date":"2026-07-31","current":-6.359353,"twenty":-45.00249,"median":-31.096524,"eighty":-6.099379,"marketCap":37240369},{"date":"2026-08-07","current":-6.77931,"twenty":-44.972922,"median":-30.724148,"eighty":-6.099379,"marketCap":39699639},{"date":"2026-08-14","current":-6.399349,"twenty":-44.943354,"median":-30.662699,"eighty":-6.099379,"marketCap":37474585},{"date":"2026-08-21","current":-4.275233,"twenty":-44.884218,"median":-29.56931,"eighty":-6.079381,"marketCap":45086610}],"updateTime":1787504215783},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629070630","title":"Nasus Pharma CEO Dan Benjamin Teleman buys 2,900 shares for $10,904","url":"https://stock-news.laohu8.com/highlight/detail?id=2629070630","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629070630?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:44","pubTimestamp":1776908689,"startTime":"0","endTime":"0","summary":"Nasus Pharma CEO Dan Benjamin Teleman reported purchase of 2,900 ordinary shares at USD 3.76.Beneficial ownership rose to 156,991 ordinary shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLxCxK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nasus Pharma CEO Dan Benjamin Teleman buys 2,900 shares for $10,904","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624291415","title":"Nasus Pharma’s CEO Makes Bold Move With Fresh Insider Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2624291415","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624291415?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:07","pubTimestamp":1775095637,"startTime":"0","endTime":"0","summary":"New insider activity at Nasus Pharma Ltd. ( ($NSRX) ) has taken place on April 1, 2026. Chief Executive Officer Dan Benjamin Teleman has signaled c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/nasus-pharmas-ceo-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/nasus-pharmas-ceo-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590027","title":"Nasus Pharma CEO Dan Benjamin Teleman buys USD 0.03 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590027","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590027?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:32","pubTimestamp":1775043131,"startTime":"0","endTime":"0","summary":"Nasus Pharma CEO Dan Benjamin Teleman bought 15,000 ordinary shares at USD 2.04.Teleman’s direct holding increased to 21,246 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL39bXHX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nasus Pharma CEO Dan Benjamin Teleman buys USD 0.03 million shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622780103","title":"Nasus Pharma director David Silberman files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622780103","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622780103?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659453,"startTime":"0","endTime":"0","summary":"Nasus Pharma director David Silberman filed an initial Form 3 statement of beneficial ownership.The filing reported a direct holding of options to buy 10,000 ordinary shares.The exercise price was USD 5.38 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDLc4rXGC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622058801","title":"Nasus Pharma files Form 3 as director Ronnie Hershman reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2622058801","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622058801?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659444,"startTime":"0","endTime":"0","summary":"Nasus Pharma director Ronnie Hershman filed an initial Form 3 disclosing indirect ownership of 1,338,463 ordinary shares.The filing also reported vested share options for 63,017 ordinary shares at an exercise price of USD 4.30.It also listed warrants for 17,970 ordinary shares held indirectly at an exercise price of USD 6.53.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL3PGGYl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622801055","title":"Nasus Pharma director Sharon Shacham files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622801055","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622801055?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659443,"startTime":"0","endTime":"0","summary":"Nasus Pharma director Sharon Shacham filed an initial Form 3 statement of beneficial ownership.The filing reported a direct share option for 10,000 ordinary shares with an exercise price of USD 5.38.The option was exercisable from March 11, 2026 and expires on December 11, 2035.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL12hgh6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622801034","title":"Nasus Pharma files Form 3 for founder, Chief Development Officer Dalia Megiddo","url":"https://stock-news.laohu8.com/highlight/detail?id=2622801034","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622801034?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659441,"startTime":"0","endTime":"0","summary":"Nasus Pharma filed an initial beneficial ownership statement for founder Dalia Megiddo, its chief development officer and a director.Megiddo reported direct ownership of 1,888,873 ordinary shares.She also reported indirect ownership of 5,195 ordinary shares.The filing listed March 18, 2026 as the event date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL4ZmZ0M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622032801","title":"Nasus Pharma files Form 3 as director Israel Isaac reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2622032801","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622032801?lang=en_us&edition=fundamental","pubTime":"2026-03-28 08:57","pubTimestamp":1774659439,"startTime":"0","endTime":"0","summary":"Nasus Pharma director Israel Isaac filed an initial Form 3 disclosure.The filing lists a direct share option for 10,000 ordinary shares with an exercise price of USD 5.38.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL59QDbj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868003","title":"Nasus Pharma Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868003?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:16","pubTimestamp":1774530960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NSRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 09:16 ET (13:16 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622855182","title":"Nasus Pharma price target lowered to $18 from $19 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855182?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:55","pubTimestamp":1774518909,"startTime":"0","endTime":"0","summary":"Citizens lowered the firm’s price target on Nasus Pharma (NSRX) to $18 from $19 and keeps an Outperform rating on the shares. Following the quarter...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-price-target-lowered-to-18-from-19-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-price-target-lowered-to-18-from-19-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622719460","title":"Nasus Pharma advances NS002 to pivotal study following Phase 2 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622719460","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622719460?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:37","pubTimestamp":1774445878,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) provided a business update highlighting recent Phase 2 results for NS002, its intranasal powder epinephrine product candidate f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-advances-ns002-to-pivotal-study-following-phase-2-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-advances-ns002-to-pivotal-study-following-phase-2-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622507964","title":"Nasus Pharma FY2025 net loss widens 282% to $5.9 million; revenue records no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2622507964","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622507964?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:14","pubTimestamp":1774444499,"startTime":"0","endTime":"0","summary":"FY2025 operating loss climbed to $4.9 million, up 355%.FY2025 research and development expenses jumped to $2,237,000, up 568% on higher NS002 development spending, including higher payroll, share-based compensation and third-party clinical research expenses.FY2025 general and administrative expenses rose to $2,667,000, up 259% on higher public company costs, higher payroll and payroll-related expenses, higher business consultant expenses and higher share-based compensation.Management said it expected existing cash and cash equivalents to be sufficient to fund operations through the second quarter of FY2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4XZdYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077033","title":"Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077033","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077033?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:00","pubTimestamp":1774443600,"startTime":"0","endTime":"0","summary":"Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen; pivotal study p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262206/0/en/Nasus-Pharma-Advances-NS002-Towards-Pivotal-Study-Following-Positive-Phase-2-Reports-Annual-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX","BK4588","BK4006","BK4585","X","BK4516","BK4520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620503982","title":"What's Going On With Nasus Pharma Stock On Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2620503982","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620503982?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:11","pubTimestamp":1773846660,"startTime":"0","endTime":"0","summary":"Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are falling and what the data shows.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/18/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/18/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51328290/whats-going-on-with-nasus-pharma-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51328290/whats-going-on-with-nasus-pharma-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","NSRX","BK4217","SMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620607476","title":"NYSE American New 52-Week Highs And Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2620607476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620607476?lang=en_us&edition=fundamental","pubTime":"2026-03-17 23:20","pubTimestamp":1773760800,"startTime":"0","endTime":"0","summary":"COMPANY                      SYMBOL       HIGH         VOLUME. -------                      ------       ----         ------. Imperial Oil                 IMO        125.44        209,995. COMPANY                      SYMBOL       LOW          VOLUME. -------                      ------       ----         ------. Credit Suisse Income Fnd     CIK          2.56         35,683. Green Circle Decarbonize     GCDT         1.80          9,147. NFT                          MI         0.5051        192,534. Nasus Pharma                 NSRX         2.70        278,185. Nuburu                       BURU       0.1756     10,216,696. Regentis Biomaterials        RGNT         3.00            810. Serina Therapeutics          SER          1.39         11,876. Copyright (c) 2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4139","NYSE","AFG","BK4007","BK4117","BK4107","RGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620749885","title":"Nasus Pharma Stock Hits 52-Week Low - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2620749885","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620749885?lang=en_us&edition=fundamental","pubTime":"2026-03-17 01:01","pubTimestamp":1773680460,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd.  shares are tumbling on Monday.The company announced topline results from its Phase 2 study of NS002, an investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis , during the premarket session.Soon after the data, the stock price surged as high as $7.29 before falling.The results demonstrated that NS002 has the potential to exceed EpiPen performance.The analysis showed statistically significant improvements in time to therapeutic threshold  and in the proportion of subjects reaching the therapeutic epinephrine threshold within the first minutes following administration.On Monday, at the five-minute mark, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen, demonstrating a favorable safety profile with no serious adverse events reported.Data released in January showed that NS002 demonstrated a higher mean peak plasma concentration  of 655 pg/ml compared to 548 pg/ml for EpiPen, and achieved peak concen","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51276658/nasus-pharma-stock-hits-52-week-low-heres-why","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51276658/nasus-pharma-stock-hits-52-week-low-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619465535","title":"Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2619465535","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619465535?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:00","pubTimestamp":1773666011,"startTime":"0","endTime":"0","summary":"WSW, NY, March 16th, 2026, FinanceWire For decades, the treatment of life-threatening allergic reactions has been defined by a paradox: a miracle d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nasus-pharmas-positive-phase-2-data-validates-the-speed-and-reliability-of-the-ns002-powder-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nasus-pharmas-positive-phase-2-data-validates-the-speed-and-reliability-of-the-ns002-powder-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450368","title":"BRIEF-Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450368","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450368?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:38","pubTimestamp":1773661115,"startTime":"0","endTime":"0","summary":"BRIEF-Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen With Accelerated Speed To Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUABFRBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450556","title":"Nasus Pharma announces topline data from Phase 2 clinical study of NS002","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450556","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450556?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:36","pubTimestamp":1773660968,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) announced top line results from its Phase 2 clinical study of NS002, the Company’s investigational intranasal epinephrine powde...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-topline-data-from-phase-2-clinical-study-of-ns002-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-topline-data-from-phase-2-clinical-study-of-ns002-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457039","title":"Nasus Pharma Phase 2 trial shows NS002 reaches 100 pg/mL epinephrine threshold in 1.69 minutes vs 3.42 minutes for EpiPen","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457039?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:31","pubTimestamp":1773660695,"startTime":"0","endTime":"0","summary":"Nasus Pharma reported top-line Phase 2 results for NS002, an investigational intranasal epinephrine powder for anaphylaxis, from an open-label study in 50 healthy adults with a history of allergic rhinitis. After a single administration, the median time to reach 100 pg/mL plasma epinephrine was 1.69 minutes with NS002 versus 3.42 minutes with EpiPen . At 5 minutes, 88.4% of participants receiving NS002 reached the 100 pg/mL threshold compared with 64.6% for EpiPen. The company said no serious adverse events were reported and that it plans to initiate a pivotal study in Q4 2026. The Phase 2 data will be presented in a conference call and webcast.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL9zpKhP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","NSRX","BK4585","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4007","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":50,"code":"91000000","status":"200"}]}}